Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

About this update from Quince Therapeutics, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/050adb88a77d2f63352c8a70b395f9bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zkm.J7_yKT6USSfbHFijJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/050adb88a77d2f63352c8a70b395f9bd","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/t6rHpAACTs0W5CDPb3zKSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/050adb88a77d2f63352c8a70b395f9bd","width":1121,"height":442}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 03, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025.","length":435,"tagName":"p"},{"type":"text","content":"A replay of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com.","length":161,"tagName":"p"},{"type":"text","content":"About Quince Therapeutics","length":25,"tagName":"p"},{"type":"text","content":"Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.","length":334,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20250403414477/en/","length":98,"tagName":"p"},{"type":"text","content":"Contacts","length":8,"tagName":"p"},{"type":"text","content":"Media & Investor Contact: Stacy RoughanQuince Therapeutics, Inc.Vice President, Corporate Communications & Investor [email protected]","length":152,"tagName":"p"}]

More updates from Quince Therapeutics, Inc.